ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board
Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its Executive Board.
- Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its Executive Board.
- Since 2016, he has held the position of Chief Operating Officer (COO) and Managing Director of ITM Medical Isotopes GmbH, a subsidiary of ITM SE.
- As a Societas Europaea (“SE”) entity, ITM SE is governed by a two-tier board structure consisting of an Executive Board and a Supervisory Board, in which the latter oversees the Executive Board.
- Under this framework, the Executive Board is comprised of members of the management team, while the Supervisory Board is generally controlled by shareholders.